3SBio Inc.
1530
주식 순위
#3688
Operating as an investment holding company, 3SBio Inc. specializes in the full... Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
주가
$1.82
시가총액
$4.56B
변동 (1일)
-3.16%
변동 (1년)
-50.30%
국가
CN
거래 3SBio Inc. (1530)
카테고리
Healthcare
3SBio Inc. (1530)의 P/E 비율
October 2026 기준 P/E 비율 TTM: 3.67
3SBio Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 3.67입니다. 2023년 말 기준 P/E 비율은 10.91였습니다.
3SBio Inc.의 P/E 비율 기록 (2012 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 3.67 | -45.32% |
| 2024 | 6.72 | -38.43% |
| 2023 | 10.91 | 10.70% |
| 2022 | 9.86 | 15.05% |
| 2021 | 8.57 | -56.24% |
| 2020 | 19.58 | -16.67% |
| 2019 | 23.49 | 23.65% |
| 2018 | 19.00 | -45.10% |
| 2017 | 34.61 | 44.58% |
| 2016 | 23.94 | -38.66% |
| 2015 | 39.02 | -21.43% |
| 2014 | 49.66 | -66.34% |
| 2013 | 147.55 | 1,190.30% |
| 2012 | 11.44 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 28.78 | 683.31% |
US
|
|
| -28.36 | -871.78% |
US
|
|
| -24.57 | -768.60% |
AU
|
|
| 30.33 | 725.44% |
NL
|
|
| - | - |
CH
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.